Indonesian Political, Business & Finance News

Oxford Study: 12 Blood Proteins Reveal Prostate Cancer Risk More Than 15 Years in Advance

| | Source: Republika Translated from Indonesian | Technology
Oxford Study: 12 Blood Proteins Reveal Prostate Cancer Risk More Than 15 Years in Advance
Image: Republika

JAKARTA — Scientists at the University of Oxford in the UK have identified several blood proteins associated with a person’s risk of developing prostate cancer more than 15 years before diagnosis. The discovery could pave the way for much earlier risk assessment, particularly to distinguish men who may develop aggressive cancer from those at lower risk.

The findings were published in the medical journal European Urology on 22 October 2026 in a study entitled “Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr”. Led by the Oxford Population Health team, the research found differences in the levels of certain proteins in blood samples taken years before men were diagnosed with prostate cancer.

In an official statement issued on Thursday (22 October 2026), the University of Oxford said the researchers found that 12 proteins were associated with prostate cancer diagnoses made more than 15 years after blood was taken. A further seven proteins were linked to the risk of aggressive prostate cancer, a type that may develop rapidly, spread or threaten patients’ lives.

The findings do not mean that prostate cancer can now be diagnosed accurately 15 years before the disease appears. The study identified an association between biological characteristics in the blood and later cancer diagnoses; it did not prove that tumours were already present when the initial samples were collected.

A Euronews report on Tuesday (27 October 2026) said the research offers a new perspective on how prostate cancer risk may develop long before a person shows clinical signs. If confirmed by further research, the findings could help doctors decide who needs more intensive testing and who can avoid unnecessary medical procedures.

The research is significant because prostate cancer does not always follow the same course. Some tumours grow very slowly and may never threaten a patient’s health, while others are aggressive, can spread to other organs and may be fatal.

This difference is one of the main challenges in treating prostate cancer. Doctors must not only detect the disease but also determine which cancers need prompt treatment and which can be monitored carefully without aggressive intervention.

How did researchers find clues more than 15 years in advance?

The Oxford study used data from the European Prospective Investigation into Cancer and Nutrition (EPIC), a long-term health research project involving participants from several European countries. The researchers analysed blood plasma samples from 982 men who were subsequently diagnosed with prostate cancer and compared them with a random group of 1,573 men from the same study population.

The two groups partly overlapped: 79 men in the random group were also among those later diagnosed with prostate cancer. The figures therefore describe the study’s analysis groups and do not represent entirely separate sets of participants.

The scientists measured more than 6,000 types of protein in the blood samples using high-throughput proteomic analysis. Participants were then followed through health records for a median period of about 16.5 years, allowing the researchers to compare protein characteristics with cancer cases that emerged years later.

Of the 982 prostate cancer cases studied, 290 were classified as aggressive. This category included high-grade tumours, advanced-stage cancer, very high levels of prostate-specific antigen (PSA) at diagnosis, and cases that resulted in death from prostate cancer.

The analysis found that 12 blood proteins were statistically associated with prostate cancer diagnosed more than 15 years after the samples were taken. The findings suggest that certain biological conditions may be associated with long-term disease risk, well before cancer is identified through clinical testing.

One protein that drew the researchers’ attention was GZMK, or granzyme K, which is produced by immune cells. It is involved in immune-system activity when the body recognises and responds to abnormal cells, including processes that may relate to surveillance of cancer-cell development.

The study found that higher levels of GZMK were associated with a lower risk of prostate cancer among men diagnosed more than 15 years later. A similar association was found for the protein ANXA2, although the scientists could not determine whether either protein directly protects against cancer or merely reflects other biological processes.

The findings raise new questions about the role of the immune system in prostate cancer development. The researchers suggest that immune responses may be linked to disease risk long before diagnosis, but the study does not prove that increasing the levels of particular proteins can prevent cancer.

More from 28 October 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/oxford-study-12-blood-proteins-reveal-prostate-cancer-risk-more-than-15-years-in-advance-1793148709)
Originally published by Republika (https://ameera.republika.co.id/berita/tnlbym451/riset-oxford-12-protein-darah-ungkap-risiko-kanker-prostat-lebih-dari-15-tahun-lebih-awal), translated from Indonesian
Print